The DOI matches its Crossref record.
Lamotrigine Monotherapy in Newly Diagnosed Untreated Epilepsy: A Double‐Blind Comparison with Phenytoin
Abstract
Summary: Purpose: Lamotrigine is an effective add‐on therapy against a range of epileptic seizure types. Comparative studies with carbamazepine (CBZ) as monotherapy in newly diagnosed epilepsy suggest similar efficacy. In this study, lamotrigine (LTG) and phenytoin (PHT) are compared. Methods: In a double‐blind parallel‐groups study, 181 patients with newly diagnosed untreated partial seizures or secondarily or primary generalised tonic‐clonic seizures were randomised to two treatment groups. One group (n = 86) received LTG titrated over 6 weeks from a starting dose of 100 mg/day. The other (n = 95) received PHT titrated from 200 mg/day. Treatment continued for <48 weeks. Results: The percentages of patients remaining on each treatment and seizure free during the last 24 and 40 weeks of the study, and times to first seizure after the first 6 weeks of treatment (dose‐titration period), did not differ significantly between the treatment groups. These were measures of efficacy. Time to discontinuation, a composite index of efficacy and safety, likewise did not distinguish between treatments. Adverse events led to discontinuation of 13 (15%) patients from LTG and 18 (19%) from PHT. The adverse‐event profile for LTG was dominated by skin rash [discontinuation of 10 (11.6%) patients compared with five (5.3%) from PHT] rather than central nervous system side effects: asthenia, somnolence, and ataxia were each significantly more frequent in the PHT group. The high rate of rash with LTG was probably due to the high starting dose and may be avoidable. A quality‐of‐life instrument, the SEALS inventory, favoured LTG. Patients taking PHT showed the biochemical changes expected of an enzyme‐inducing drug, whereas those taking LTG did not. Conclusions: LTG and PHT monotherapy were similarly effective against these seizure types in patients with newly diagnosed epilepsy. LTG was better tolerated, more frequently causing rash, but with a lower incidence of central nervous system side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., Cramp, C., Cockerell, O. C., Cooper, P. N., Doughty, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60460-7 · Cited by 976
Glauser, T., Ben‐Menachem, E., Bourgeois, B., Cnaan, A., Guerreiro, C., Kälviäinen, R., Mattson, R., French, J. A., Perucca, E., Tomson, T., et al. (2013) · Epilepsia · doi:10.1111/epi.12074 · Cited by 721
French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000123693.82339.fc · Cited by 654
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy
Brodie, M. J., Perucca, E., Ryvlin, P., Ben-Menachem, E., & Meencke, H.-J. (2007) · Neurology · doi:10.1212/01.wnl.0000252941.50833.4a · Cited by 467
Picard, D., Janela, B., Descamps, V., D’Incan, M., Courville, P., Jacquot, S., Rogez, S., Mardivirin, L., Moins-Teisserenc, H., Toubert, A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001116 · Cited by 397
Metadata
- Authors
- Steiner, T. J., Dellaportas, C. I., Findley, L. J., Gross, M., Gibberd, F. B., Perkin, G. D., Park, D. M., & Abbott, R.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 1999-05
- Volume
- 40
- Issue
- 5
- Pages
- 601-607
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2095558066
- Cited by
- 234
- References
- 0
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lamotrigine Monotherapy in Newly Diagnosed Untreated Epilepsy: A Double‐Blind Comparison with Phenytoin. https://app.cochat.ai/papers/10.1111/j.1528-1157.1999.tb05562.x
- The paper
- Steiner, T. J., Dellaportas, C. I., Findley, L. J., Gross, M., Gibberd, F. B., Perkin, G. D., Park, D. M., & Abbott, R. (1999). Lamotrigine Monotherapy in Newly Diagnosed Untreated Epilepsy: A Double‐Blind Comparison with Phenytoin. Epilepsia. https://doi.org/10.1111/j.1528-1157.1999.tb05562.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.